The effect of bucolome and amiodarone, inhibitors of CYP2C9, on the pharmacokinetics of losartan

被引：0
|
作者：
Takagi, Miho [1 ]
Kobayashi, Mariko [1 ]
Fukumoto, Kyoko [1 ]
Ueno, Kazuyuki [1 ]
机构：
[1] Niigata Univ, Dept Pharmaceut Sci, Niigata, Japan
来源：
THERAPEUTIC DRUG MONITORING | 2007年 / 29卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
240
引用
收藏
页码：534 / 535
页数：2
相关论文
共 50 条
  • [21] Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy
    Mansi Shah
    Meixiang Xu
    Poonam Shah
    Xiaoming Wang
    Shannon M. Clark
    Maged Costantine
    Holly A. West
    Tatiana N. Nanovskaya
    Mahmoud S. Ahmed
    Sherif Z. Abdel-Rahman
    Raman Venkataramanan
    Steve N. Caritis
    Gary D. V. Hankins
    Erik Rytting
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 83 - 89
  • [22] Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy
    Shah, Mansi
    Xu, Meixiang
    Shah, Poonam
    Wang, Xiaoming
    Clark, Shannon M.
    Costantine, Maged
    West, Holly A.
    Nanovskaya, Tatiana N.
    Ahmed, Mahmoud S.
    Abdel-Rahman, Sherif Z.
    Venkataramanan, Raman
    Caritis, Steve N.
    Hankins, Gary D. V.
    Rytting, Erik
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (01) : 83 - 89
  • [23] CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians
    Vianna-Jorge, R
    Perini, JA
    Rondinelli, E
    Suarez-Kurtz, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (01) : 18 - 26
  • [24] Metabolism of dapsone by CYP2C9 and its effect on CYP2C9 substrates.
    Tracy, TS
    Metz, CA
    Korzekwa, KR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 152 - 152
  • [25] EFFECT OF CYP2C8 AND CYP2C9 AND GENDER ON PIOGLITAZONE PHARMACOKINETICS IN HEALTHY VOLUNTEERS
    Roman, M.
    Ochoa, M. D.
    Talegon, M.
    Rivas, A.
    Prieto, R.
    Cabaleiro, T.
    Abad, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 113 : 23 - 23
  • [26] Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers
    Ochoa, Dolores
    Prieto-Perez, Rocio
    Roman, Manuel
    Talegon, Maria
    Rivas, Angela
    Galicia, Ignacio
    Abad-Santos, Francisco
    Cabaleiro, Teresa
    PHARMACOGENOMICS, 2015, 16 (09) : 939 - 948
  • [27] Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans
    Lee, CR
    Pieper, JA
    Frye, RF
    Hinderliter, AL
    Blaisdell, JA
    Goldstein, JA
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (01): : 84 - 91
  • [28] CYP2C9 genetic variants and losartan oxidation in a Turkish population
    Melih O. Babaoglu
    Umit Yasar
    Mia Sandberg
    Erik Eliasson
    Marja-Liisa Dahl
    S. Oguz Kayaalp
    Atila Bozkurt
    European Journal of Clinical Pharmacology, 2004, 60 : 337 - 342
  • [29] CYP2C9 genetic variants and losartan oxidation in a Turkish population
    Babaoglu, MO
    Yasar, U
    Sandberg, M
    Eliasson, E
    Dahl, ML
    Kayaalp, SO
    Bozkurt, A
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (05) : 337 - 342
  • [30] Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects
    Bae, Jung-Woo
    Kim, Ji-Hong
    Choi, Chang-Ik
    Kim, Mi-Jeong
    Kim, Hyung-Ji
    Byun, Seong-Ae
    Chang, Young-Soon
    Jang, Choon-Gon
    Park, Young-Seo
    Lee, Seok-Yong
    ARCHIVES OF PHARMACAL RESEARCH, 2009, 32 (02) : 269 - 273
12345